Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma

Cell Death and Differentiation

Volumn 20, Issue 9, 2013, Pages 1250-1256

  Namekata, K ^a   Kimura, A ^a   Kawamura, K ^a   Guo, X ^a   Harada, C ^a   Tanaka, K ^b   Harada, T ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Dock3; glaucoma; glutamate; neuroprotection; oxidative stress

Indexed keywords

DOCK3 PROTEIN; EXCITATORY AMINO ACID TRANSPORTER; GUANINE NUCLEOTIDE EXCHANGE FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; GENE OVEREXPRESSION; LOW TENSION GLAUCOMA; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA DEGENERATION; RETINA GANGLION CELL;

MUS; MUS MUSCULUS;

ANIMALS; APOPTOSIS; BINDING SITES; CARRIER PROTEINS; CELL LINE; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID TRANSPORTER 1; GLUTAMIC ACID; HEK293 CELLS; HUMANS; LOW TENSION GLAUCOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, N-METHYL-D-ASPARTATE; RETINA; RETINAL DEGENERATION; RETINAL GANGLION CELLS; SIGNAL TRANSDUCTION;

EID: 84882254066     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.91     Document Type: Article

References (57)

1. Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gö tz J. Dendritic function of tau mediates amyloid-b toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-397.
2. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-b protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-2875.
3. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010; 65: 178-190.
4. Zhang K, Zhang L, Weinerb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012; 11: 541-559.
5. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009; 30: 563-569.
6. Harada T, Harada C, Nakamura K, Quah HM, Okumura A, Namekata K et al. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 2007; 117: 1763-1770.
7. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013; 14: 383-400.
8. Kalbaugh TL, Zhang J, Diamond JS. Coagonist release modulates NMDA receptor subtype contributions at synaptic inputs to retinal ganglion cells. J Neurosci 2009; 29: 1469-1479.
9. Brandstä tter JH, Hartveit E, Sassoè-Pognetto M, Wä ssle H. Expression of NMDA and high-affinity kainate receptor subunit mRNAs in the adult rat retina. Eur J Neurosci 1994; 6: 1100-1112.
10. Watanabe M, Mishina M, Inoue Y. Differential distributions of the NMDA receptor channel subunit mRNAs in the mouse retina. Brain Res 1994; 634: 328-332.
11. Gründer T, Kohler K, Kaletta A, Guenther E. The distribution and developmental regulation of NMDA receptor subunit proteins in the outer and inner retina of the rat. J Neurobiol 2000; 44: 333-342.
12. Sobczyk A, Scheuss V, Svoboda K. NMDA receptor subunit-dependent [Ca2\+] signaling in individual hippocampal dendritic spines. J Neurosci 2005 29; 25: 6037-6046.
13. Yashiro K, Philpot BD. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008; 55: 1081-1094.
14. Roche KW, Standley S, McCallum J, Dune LyC, Ehlers MD, Wenthold RJ. Molecular determinants of NMDA receptor internalization. Nat Neurosci 2001; 4: 794-802.
15. Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K et al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR12 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem 2001; 276: 693-699.
16. Rong Y, Lu X, Bernard A, Khrestchatisky M, Baudry M. Tyrosine phosphorylation of ionotropic glutamate receptors by Fyn or Src differentially modulates their susceptibility to calpain and enhances their binding to spectrin and PSD-95. J Neurochem 2001; 79: 382-390.
17. Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 2004; 5: 317-328.
18. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 2003; 97: 55-85.
19. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A et al. Alzheimer amyloid-b oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012; 15: 1227-1235.
20. Namekata K, Enokido Y, Iwasawa K, Kimura H. MOCA induces membrane spreading by activating Rac1. J Biol Chem 2004; 279: 14331-14337.
21. Namekata K, Harada C, Taya C, Guo X, Kimura H, Parada LF et al. Dock3 induces axonal outgrowth by stimulating membrane recruitment of the WAVE complex. Proc Natl Acad Sci USA 2010; 107: 7586-7591.
22. Namekata K, Harada C, Guo X, Kimura A, Kittaka D, Watanabe H et al. Dock3 stimulates axonal outgrowth via GSK-3b-mediated microtubule assembly. J Neurosci 2012; 32: 264-274.
23. Kashiwa A, Yoshida H, Lee S, Paladino T, Liu Y, Chen Q et al. Isolation and characterization of novel presenilin binding protein. J Neurochem 2000; 75: 109-116.
24. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68: 270-281.
25. Chen Q, Yoshida H, Schubert D, Maher P, Mallory M, Masliah E. Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation. Am J Pathol 2001; 159: 1597-1602.
26. Sun L, Liu O, Desai J, Karbassi F, Sylvain MA, Shi A et al. CED-10/Rac1 regulates endocytic recycling through the RAB-5 GAP TBC-2. PLoS Genet 2012; 8: e1002785.
27. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A et al. Targeting amyloid-b in glaucoma treatment. Proc Natl Acad Sci USA 2007; 104: 13444-13449.
28. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci 2006; 246: 79-83.
29. Harada C, Nakamura K, Namekata K, Okumura A, Mitamura Y, Iizuka Y et al. Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis in vivo. Am J Pathol 2006; 168: 261-269.
30. Harada C, Namekata K, Guo X, Yoshida H, Mitamura Y, Matsumoto Y et al. ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma. Cell Death Differ 2010; 17: 1751-1759.
31. Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 1940-1944.
32. Zoia CP, Tagliabue E, Isella V, Begni B, Fumagalli L, Brighina L et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol Aging 2005; 26: 825-832.
33. Bai N, Hayashi H, Aida T, Namekata K, Harada T, Mishina M et al. Dock3 interaction with a glutamate-receptor NR2D subunit protects neurons from excitotoxicity. Mol Brain 2013; 6: 22.
34. Hawasli AH, Benavides DR, Nguyen C, Kansy JW, Hayashi K, Chambon P et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci 2007; 10: 880-886.
35. Wu HY, Hsu FC, Gleichman AJ, Baconguis I, Coulter DA, Lynch DR. Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems. J Biol Chem 2007; 282 2007 5-20087.
36. Mao LM, Wang W, Chu XP, Zhang GC, Liu XY, Yang YJ et al. Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat Neurosci 2009; 12: 602-610.
37. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P et al. Ab-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 2010; 30: 5948-5957.
38. Osborne NN, del Olmo-Aguado S. Maintenance of retinal ganglion cell mitochondrial functions as a neuroprotective strategy in glaucoma. Curr Opin Pharmacol 2013; 13: 16-22.
39. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2005; 46: 877-883.
40. Nishitoh H, Kadowaki H, Nagai A, Maruyama T, Yokota T, Fukutomi H et al. ALS-linked mutant SOD1 induces ER stress-and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008; 22: 1451-1464.
41. Hattori K, Naguro I, Runchel C, Ichijo H. The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 2009; 7: 9.
42. Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, Ji H et al. Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med 2010; 2: 504-515.
43. Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider D et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 271-279.
44. Hollands H, Johnson D, Hollands S, Simel DL, Jinapriya D, Sharma S. Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. JAMA 2013; 309: 2035-2042.
45. Bouhenni RA, Dunmire J, Sewell A, Edward DP. Animal models of glaucoma. J Biomed Biotechnol 2012; 2012: 692609.
46. Harvey AR, Hellström M, Rodger J. Gene therapy and transplantation in the retinofugal pathway. Prog Brain Res 2009; 175: 151-161.
47. Bessero AC, Clarke PG. Neuroprotection for optic nerve disorders. Curr Opin Neurol 2010; 23: 10-15.
48. Harada C, Guo X, Namekata K, Kimura A, Nakamura K, Tanaka K et al. Glia-and neuronspecific functions of TrkB signalling during retinal degeneration and regeneration. Nat Commun 2011; 2: 189.
49. Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011; 4: 15.
50. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11: 539-551.
51. Harada T, Harada C, Kohsaka S, Wada E, Yoshida K, Ohno S et al. Microglia-Mü ller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci 2002; 22: 9228-9236.
52. Katome T, Namekata K, Guo X, Semba K, Kittaka D, Kawamura K et al. Inhibition of ASK1-p38 pathway prevents neural cell death following optic nerve injury. Cell Death Differ 2013; 20: 270-280.
53. Quigley HA. Glaucoma. Lancet 2011; 377: 1367-1377.
54. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-851.
55. Namekata K, Harada C, Kohyama K, Matsumoto Y, Harada T. Interleukin-1 stimulates glutamate uptake in glial cells by accelerating membrane trafficking of Na\+/K\+-ATPase via actin depolymerization. Mol Cell Biol 2008; 28: 3273-3280.
56. Harada T, Harada C, Watanabe M, Inoue Y, Sakagawa T, Nakayama N et al. Functions of the two glutamate transporters GLAST and GLT-1 in the retina. Proc Natl Acad Sci USA 1998; 95: 4663-4666.
57. Barres BA, Silverstein BE, Corey DP, Chun LL. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1988; 1: 791-803.